Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

November 10, 2011

Primary Completion Date

November 14, 2016

Study Completion Date

January 17, 2017

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

Placebos

"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle(stop interventing until the disease progress)~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"

DRUG

Sulijia

"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle(stop interventing until the disease progress)~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"

Trial Locations (37)

Unknown

Bengbu medical college affiliated hospital, Bengbu

The first affiliated hospital, anhui medical university, Hefei

The second affiliated hospital, anhui medical university, Hefei

Beijing Chest Hospital, Beijing

Cancer Hospital Chinese Academy of Medical Science, Beijing

Peking Union Medical College Hospital, Beijing

The First Affiliated Hospital of Fujian Medical University, Fuzhou

First Affiliated Hospital of Xiamen University, Xiamen

The First Affiliated Hospital of Guangzhou Medical College, Guangzhou

The First Affiliated Hospital of Shantou Medical School, Shantou

Guilin medical college affiliated hospital, Guilin

The first affiliated hospital of xinxiang medical college, Xinxiang

The Oncology Center of Wuhan Union Hospital, Wuhan

Zhongnan hospital of Wuhan University, Wuhan

Changsha Central Hospital, Changsha

The Second Xiangya Hospital of Central South University, Changsha

Yueyang city people's hospital, Yueyang

The first People's Hospital of Changzhou, Changzhou

Jiangsu Cancer Hospital, Nanjing

The People 's Liberation Army Eighth Hospital, Nanjing

Affiliate Hospital of Nantong University, Nantong

The first hospital affiliated to suzhou university, Suzhou

The Second Affiliated Hospital of Soochow University, Suzhou

The Fourth People's Hospital of Wuxi, Wuxi

Xuzhou medical college affiliated hospital, Xuzhou

The First Hospital of Jilin University, Changchun

People's hospital SiPingShi center, Siping

Yanbian university hospital, Yanji

The tumor hospital of liaoning province, Shenyang

Ningxia medical university general hospital, Yinchuan

Binzhou medical school affiliated hospital, Binzhou

Jinan Central Hospital Affiliated of Shandong University, Jinan

Linyi Cancer Hospital, Linyi

Shanghai General Hospital, Shanghai

West China Hospital ,Sichuan University, Chengdu

The second people's hospital of yibin city, Yibin

Zhejiang cancer hospital, Hangzhou

All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT03117335 - Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter